Divi's Labs Recommends ₹30 Dividend as FY26 Profit Climbs 17%

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorAnanya Iyer|Published at:
Divi's Labs Recommends ₹30 Dividend as FY26 Profit Climbs 17%
Overview

Divi's Laboratories reported a strong fiscal year 2026, with profit after tax climbing 17% to ₹2568 crore. The company also recommended a final dividend of ₹30 per share, pending shareholder approval at the upcoming AGM.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Divi's Laboratories Reports Strong FY26 Results, Recommends ₹30 Dividend

Divi's Laboratories announced its audited financial results for the fourth quarter and the full fiscal year 2026. The company reported a consolidated profit after tax (PAT) of ₹2568.00 crore for FY26, marking a 17% increase from ₹2191.00 crore in FY25. Consolidated total income for FY26 stood at ₹11067.00 crore. For the fourth quarter of FY26, the PAT was ₹751.00 crore.

The company's board has recommended a final dividend of ₹30.00 per share. This represents a 1,500% payout on the ₹2.00 face value of the shares.

Why This Matters to Investors

The increase in profit and revenue signals the company's strong operational performance and solid market standing. The recommended dividend offers shareholders a direct financial return on their investment.

However, investors should be aware of a one-time exceptional charge of ₹74.00 crore recognized in FY26. This charge is related to the implementation of new labor codes and impacted the profit before tax for the period.

Financial Performance Overview

In the previous fiscal year, FY25, Divi's Laboratories reported a consolidated PAT of ₹2191.00 crore on a revenue of ₹10560.00 crore. The company has a history of consistent growth, driven by its manufacturing expertise in active pharmaceutical ingredients (APIs) and intermediates.

Next Steps for Shareholders

Shareholders will vote on the recommended dividend at the upcoming 36th Annual General Meeting (AGM) on August 10, 2026. If approved, the dividend will be distributed to eligible shareholders following the AGM.

Potential Risks

A key risk identified is the ₹74.00 crore exceptional charge due to new labor code implementations, which affected FY26 profitability. Future impacts from these labor codes and other potential regulatory changes could influence operational costs and overall profitability.

Key Financials and Dates

  • Consolidated FY26 Revenue: ₹10560.00 crore (compared to ₹9360.00 crore in FY25)
  • Consolidated FY26 Profit After Tax: ₹2568.00 crore (compared to ₹2191.00 crore in FY25)
  • Recommended Dividend per Share: ₹30.00
  • Record Date for Dividend: July 24, 2026
  • AGM Date for Dividend Approval: August 10, 2026

What to Watch

Investors should continue to monitor the company's quarterly performance and await the final decision on the dividend payout.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.